Lineage Cell Therapeutics, Inc. (LCTX.TA)
ILA 191.3
(5.4%)
ILA 191.3
(5.4%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 8.94 Million | 14.7 Million | 3.89 Million | 773 Thousand | 1.47 Million | 1.41 Million |
| Cost of Revenue | 671 Thousand | 728 Thousand | 1.42 Million | 385 Thousand | 412 Thousand | 302 Thousand |
| Gross Profit | 8.27 Million | 13.97 Million | 2.47 Million | 388 Thousand | 1.06 Million | 1.11 Million |
| Operating Expenses | 33 Million | 36.49 Million | 51.68 Million | 26.83 Million | 39.94 Million | 42.1 Million |
| Selling, General and Administrative Expenses | 17.3 Million | 22.5 Million | 18.21 Million | 15.57 Million | 24.03 Million | 24.72 Million |
| Research and Development Expenses | 15.7 Million | 13.98 Million | 33.91 Million | 12.31 Million | 17.94 Million | 20.95 Million |
| Other Expenses | - | -2.15 Million | 1.48 Million | 2.88 Million | 2.53 Million | -1.31 Million |
| Cost and Expenses | 33.67 Million | 37.22 Million | 53.1 Million | 27.22 Million | 40.35 Million | 42.41 Million |
| Operating Income | -24.73 Million | -22.52 Million | -49.21 Million | -26.44 Million | -38.87 Million | -41.79 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -1.8 Million | 541 Thousand | -4.7 Million | -1.23 Million | -7.4 Million | -346 Thousand |
| Earnings before Tax | -23.28 Million | -25.81 Million | -43.27 Million | -21.92 Million | -19.23 Million | -47.13 Million |
| Net Income | -21.48 Million | -26.27 Million | -43.01 Million | -20.64 Million | -11.7 Million | -45.99 Million |
| Earnings Per Share Basic | -0.12 | -0.15 | -0.26 | -0.14 | -0.08 | -0.36 |
| Earnings Per Share Diluted | -0.12 | -0.15 | -0.26 | -0.14 | -0.08 | -0.36 |
| Weighted Average Shares Outstanding | 172.66 Million | 169.79 Million | 164.5 Million | 150.04 Million | 145.53 Million | 126.9 Million |
| Weighted Average Shares Outstanding (Diluted) | 172.66 Million | 169.79 Million | 164.5 Million | 150.04 Million | 145.53 Million | 126.9 Million |
| Gross Margin | 0.92 | 0.95 | 0.63 | 0.50 | 0.72 | 0.79 |
| EBIT Margin | -2.69 | -1.35 | -13.55 | -32.36 | -36.74 | -22.73 |
| Profit Margin | -2.40 | -1.79 | -11.04 | -26.71 | -7.92 | -32.48 |
| EBITDA | -24.04 Million | -21.79 Million | -48.33 Million | -24.4 Million | -35.87 Million | -37.72 Million |
| Earnings Before Tax Margin | -2.77 | -1.53 | -12.63 | -34.21 | -26.30 | -29.52 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1.4 Million | 1.44 Million | 8.94 Million | 2.08 Million | 1.24 Million | 3.22 Million |
| Cost of Revenue | 44 Thousand | 98 Thousand | 671 Thousand | 256 Thousand | 169 Thousand | 127 Thousand |
| Gross Profit | 1.36 Million | 1.34 Million | 8.27 Million | 1.83 Million | 1.07 Million | 3.09 Million |
| Operating Expenses | 7.23 Million | 8 Million | 33 Million | 8.19 Million | 7.78 Million | 8.12 Million |
| Selling, General and Administrative Expenses | 4.36 Million | 4.99 Million | - | 4.28 Million | 4.04 Million | 4.24 Million |
| Research and Development Expenses | 2.86 Million | 3.01 Million | - | 3.9 Million | 3.74 Million | 3.87 Million |
| Other Expenses | 19 Thousand | - | -4000.00 | 1.24 Million | -826 Thousand | -411 Thousand |
| Cost and Expenses | 7.27 Million | 8.1 Million | 33.67 Million | 8.45 Million | 7.95 Million | 8.24 Million |
| Operating Income | -5.86 Million | -6.66 Million | -24.73 Million | -6.36 Million | -6.7 Million | -5.02 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -88 Thousand | -119 Thousand | -1.8 Million | -338 Thousand | -421 Thousand | -206 Thousand |
| Earnings before Tax | -5.77 Million | -6.55 Million | -23.28 Million | -4.71 Million | -7.15 Million | -5.2 Million |
| Net Income | -5.76 Million | -6.54 Million | -21.48 Million | -4.77 Million | -7.11 Million | -5.22 Million |
| Earnings Per Share Basic | -0.03 | -0.04 | - | -0.03 | -0.04 | -0.03 |
| Earnings Per Share Diluted | -0.03 | -0.04 | - | -0.03 | -0.04 | -0.03 |
| Weighted Average Shares Outstanding | 188.81 Million | 182.9 Million | 172.66 Million | 175.01 Million | 174.86 Million | 170.59 Million |
| Weighted Average Shares Outstanding (Diluted) | 188.81 Million | 182.9 Million | 172.66 Million | 175.01 Million | 174.86 Million | 170.59 Million |
| Gross Margin | 0.97 | 0.93 | 0.92 | 0.88 | 0.86 | 0.96 |
| EBIT Margin | -3.79 | -4.24 | - | -2.96 | -5.19 | -1.46 |
| Profit Margin | -4.09 | -4.53 | -2.40 | -2.29 | -5.71 | -1.62 |
| EBITDA | -5.33 Million | -6.12 Million | - | -6.18 Million | -6.46 Million | -4.7 Million |
| Earnings Before Tax Margin | -4.17 | -4.61 | -2.77 | -3.05 | -5.38 | -1.56 |
ALSE
OGC
ACRE
0IFJ
353810
BAZA3